Trial Profile
Retrospective study investigating the risk of autoimmune disease occurrence post treatment with immunomodulatory drugs in patients with multiple myeloma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 Dec 2015
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary) ; Thalidomide (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- 11 Dec 2015 New trial record